{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:46:11Z","timestamp":1785811571280,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M731453, 2024T170367"],"award-info":[{"award-number":["2023M731453, 2024T170367"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor-initiating cells (TICs) are central to cancer progression and metastasis; however, they remain challenging to target therapeutically. Here, using a breast-specific CYP4Z1-transgenic MMTV-PyMT mouse model, we show that CYP4Z1 notably accelerates tumor initiation, enlarges tumor size, promotes metastasis, and expands TIC populations. Multi-omics analyses reveal that CYP4Z1\n                    <jats:sup>+<\/jats:sup>\n                    epithelial cells exhibit enhanced stemness and reduced differentiation compared with CYP4Z1\n                    <jats:sup>\u2212<\/jats:sup>\n                    counterparts. Notably, ISG15-mediated ISGylation of CYP4Z1 at lysine residues K259, K279, and K502 stabilizes the protein, augments its enzymatic function, promotes endoplasmic reticulum localization, and prevents ubiquitination, thereby amplifying TIC-like properties. This modification further upregulates triglyceride synthesis and promotes lipid droplet formation. Finally, we develop BM-51, a specific CYP4Z1 inhibitor that attenuates TIC-like traits and enhances chemotherapy efficacy. Our findings highlight the therapeutic potential of targeting CYP4Z1 and its ISGylation to disrupt TIC-driven breast cancer progression.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01766-4","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:03:47Z","timestamp":1782986627000},"page":"2202-2222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression"],"prefix":"10.1038","volume":"58","author":[{"given":"Yin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-9598","authenticated-orcid":false,"given":"Hong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-4974","authenticated-orcid":false,"given":"Lufeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1766_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J Clin 73, 17\u201348 (2023).","journal-title":"CA Cancer J Clin"},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"key":"1766_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-020-00901-6","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol 13, 60 (2020).","journal-title":"J Hematol Oncol"},{"key":"1766_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05475-6","volume":"612","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature 612, 555\u2013563 (2022).","journal-title":"Nature"},{"key":"1766_CR5","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cancers11050732","volume":"11","author":"M Shibata","year":"2019","unstructured":"Shibata, M. & Hoque, M. O. Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers 11, 732 (2019).","journal-title":"Cancers"},{"key":"1766_CR7","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1158\/0008-5472.CAN-03-0849","volume":"64","author":"MA Rieger","year":"2004","unstructured":"Rieger, M. A. et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 64, 2357\u20132364 (2004).","journal-title":"Cancer Res."},{"key":"1766_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/1873-3468.12608","volume":"591","author":"C Li","year":"2017","unstructured":"Li, C. et al. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer. FEBS Lett. 591, 991\u20131000 (2017).","journal-title":"FEBS Lett."},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2174\/1381612823666170207150156","volume":"23","author":"X Yang","year":"2017","unstructured":"Yang, X., Hutter, M., Goh, W. W. B. & Bureik, M. CYP4Z1 \u2014 a human cytochrome P450 enzyme that might hold the key to curing breast cancer. Curr. Pharm. Des. 23, 2060\u20132064 (2017).","journal-title":"Curr. Pharm. Des."},{"key":"1766_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/cmi.2017.21","volume":"14","author":"V Nunna","year":"2017","unstructured":"Nunna, V., Jalal, N. & Bureik, M. Anti-CYP4Z1 autoantibodies detected in breast cancer patients. Cell Mol Immunol 14, 572\u2013574 (2017).","journal-title":"Cell Mol Immunol"},{"key":"1766_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.taap.2012.07.019","volume":"264","author":"W Yu","year":"2012","unstructured":"Yu, W. et al. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol. Appl. Pharmacol. 264, 73\u201383 (2012).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1766_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.mce.2016.03.012","volume":"427","author":"L Zheng","year":"2016","unstructured":"Zheng, L. et al. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol. Cell. Endocrinol. 427, 133\u2013142 (2016).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-015-3298-2","volume":"150","author":"L Zheng","year":"2015","unstructured":"Zheng, L., Li, X., Gu, Y., Lv, X. & Xi, T. The 3\u2019UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1. Breast Cancer Res Treat 150, 105\u2013118 (2015).","journal-title":"Breast Cancer Res Treat"},{"key":"1766_CR14","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.3390\/cancers12102848","volume":"12","author":"NA Wilkinson","year":"2020","unstructured":"Wilkinson, N. A., Mnuskin, K. S., Ashton, N. W. & Woodgate, R. Ubiquitin and ubiquitin-like proteins are essential regulators of DNA damage bypass. Cancers 12, 2848 (2020).","journal-title":"Cancers"},{"key":"1766_CR15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/molecules28031337","volume":"28","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y. et al. The functional roles of ISG15\/ISGylation in cancer. Molecules 28, 1337 (2023).","journal-title":"Molecules"},{"key":"1766_CR16","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1158\/0008-5472.CAN-14-1354","volume":"74","author":"B Sainz Jr","year":"2014","unstructured":"Sainz, B. Jr, Mart\u00edn, B., Tatari, M., Heeschen, C. & Guerra, S. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 74, 7309\u20137320 (2014).","journal-title":"Cancer Res"},{"key":"1766_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16395-2","volume":"11","author":"S Alcal\u00e1","year":"2020","unstructured":"Alcal\u00e1, S. et al. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Nat Commun 11, 2682 (2020).","journal-title":"Nat Commun"},{"key":"1766_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13046-023-02751-9","volume":"42","author":"T Xu","year":"2023","unstructured":"Xu, T. et al. ISG15 and ISGylation modulates cancer stem cell-like characteristics in promoting tumor growth of anaplastic thyroid carcinoma. J Exp Clin Cancer Res 42, 182 (2023).","journal-title":"J Exp Clin Cancer Res"},{"key":"1766_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41388-019-0992-2","volume":"39","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation. Oncogene 39, 546\u2013559 (2020).","journal-title":"Oncogene"},{"key":"1766_CR20","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1111\/jcmm.16503","volume":"25","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer. J Cell Mol Med 25, 4395\u20134407 (2021).","journal-title":"J Cell Mol Med"},{"key":"1766_CR21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","volume":"26","author":"HR Ali","year":"2015","unstructured":"Ali, H. R. et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 26, 1488\u20131493 (2015).","journal-title":"Ann Oncol"},{"key":"1766_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 38, 675\u2013678 (2020).","journal-title":"Nat Biotechnol"},{"key":"1766_CR23","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.labinv.2023.100258","volume":"103","author":"A Coutant","year":"2023","unstructured":"Coutant, A. et al. Spatial transcriptomics reveal pitfalls and opportunities for the detection of rare high-plasticity breast cancer subtypes. Lab Invest 103, 100258 (2023).","journal-title":"Lab Invest"},{"key":"1766_CR24","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"1766_CR25","doi-asserted-by":"publisher","first-page":"e2205395","DOI":"10.1002\/advs.202205395","volume":"10","author":"Y-M Liu","year":"2023","unstructured":"Liu, Y.-M. et al. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci (Weinh) 10, e2205395 (2023).","journal-title":"Adv Sci (Weinh)"},{"key":"1766_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14, 7 (2013).","journal-title":"BMC Bioinform"},{"key":"1766_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17, 218 (2016).","journal-title":"Genome Biol"},{"key":"1766_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","volume":"23","author":"J Frede","year":"2021","unstructured":"Frede, J. et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat. Cell Biol 23, 1199\u20131211 (2021).","journal-title":"Nat. Cell Biol"},{"key":"1766_CR29","unstructured":"Trapnell, C., Cacchiarelli, D. & Qiu, X. Monocle: cell counting, differential expression, and trajectory analysis for single-cell RNA-Seq experiments. Bioconductor https:\/\/www.bioconductor.org\/packages\/release\/bioc\/html\/monocle.html (2017)."},{"key":"1766_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun 12, 1088 (2021).","journal-title":"Nat Commun"},{"key":"1766_CR31","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1093\/nar\/gkab043","volume":"49","author":"M Elosua-Bayes","year":"2021","unstructured":"Elosua-Bayes, M., Nieto, P., Mereu, E., Gut, I. & Heyn, H. SPOTlight: seeded NMF regression to deconvolute spatial transcriptomics spots with single-cell transcriptomes. Nucleic Acids Res 49, e50 (2021).","journal-title":"Nucleic Acids Res"},{"key":"1766_CR32","doi-asserted-by":"publisher","first-page":"15749","DOI":"10.1021\/acs.jmedchem.2c01320","volume":"65","author":"Y Yuan","year":"2022","unstructured":"Yuan, Y. et al. Identification of a novel potent CYP4Z1 inhibitor attenuating the stemness of breast cancer cells through lead optimization. J Med Chem 65, 15749\u201315769 (2022).","journal-title":"J Med Chem"},{"key":"1766_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347, 70\u201378 (2009).","journal-title":"J Immunol Methods"},{"key":"1766_CR34","first-page":"954","volume":"12","author":"CT Guy","year":"1992","unstructured":"Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954\u2013961 (1992).","journal-title":"Mol Cell Biol"},{"key":"1766_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ccr.2008.01.011","volume":"13","author":"H Kouros-Mehr","year":"2008","unstructured":"Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141\u2013152 (2008).","journal-title":"Cancer Cell"},{"key":"1766_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccr.2014.04.027","volume":"26","author":"L Wan","year":"2014","unstructured":"Wan, L. et al. MTDH\u2013SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer Cell 26, 92\u2013105 (2014).","journal-title":"Cancer Cell"},{"key":"1766_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature10694","volume":"481","author":"I Malanchi","year":"2011","unstructured":"Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85\u201389 (2011).","journal-title":"Nature"},{"key":"1766_CR38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/ncb3425","volume":"18","author":"T Ni","year":"2016","unstructured":"Ni, T. et al. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nat Cell Biol 18, 1221\u20131232 (2016).","journal-title":"Nat Cell Biol"},{"key":"1766_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ncb1530","volume":"9","author":"ML Asselin-Labat","year":"2007","unstructured":"Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9, 201\u2013209 (2007).","journal-title":"Nat Cell Biol"},{"key":"1766_CR40","doi-asserted-by":"publisher","first-page":"e2205395","DOI":"10.1002\/advs.202205395","volume":"10","author":"YM Liu","year":"2023","unstructured":"Liu, Y. M. et al. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci (Weinh) 10, e2205395 (2023).","journal-title":"Adv Sci (Weinh)"},{"key":"1766_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114739119","volume":"119","author":"X van Dierendonck","year":"2022","unstructured":"van Dierendonck, X. et al. Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages. Proc. Natl Acad. Sci. USA 119, e2114739119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1766_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/tox.24050","volume":"39","author":"H Qin","year":"2024","unstructured":"Qin, H. et al. 1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1. Environ Toxicol 39, 1505\u20131520 (2024).","journal-title":"Environ Toxicol"},{"key":"1766_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85188-4","volume":"11","author":"YM Al-Saraireh","year":"2021","unstructured":"Al-Saraireh, Y. M. et al. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep 11, 5581 (2021).","journal-title":"Sci Rep"},{"key":"1766_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0826-9","volume":"17","author":"A Majumder","year":"2018","unstructured":"Majumder, A. et al. Enhanced expression of histone chaperone APLF associate with breast cancer. Mol Cancer 17, 76 (2018).","journal-title":"Mol Cancer"},{"key":"1766_CR45","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3332\/ecancer.2020.1114","volume":"14","author":"YM Al-Saraireh","year":"2020","unstructured":"Al-Saraireh, Y. M. et al. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Ecancermedicalscience 14, 1114 (2020).","journal-title":"Ecancermedicalscience"},{"key":"1766_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-021-06435-w","volume":"191","author":"C Khayeka-Wandabwa","year":"2022","unstructured":"Khayeka-Wandabwa, C., Zhao, J., Pathak, J. L., Wu, H. & Bureik, M. Upregulation of estrogen receptor alpha (ER\u03b1) expression in transgenic mice expressing human CYP4Z1. Breast Cancer Res Treat 191, 319\u2013326 (2022).","journal-title":"Breast Cancer Res Treat"},{"key":"1766_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature20829","volume":"541","author":"A Britschgi","year":"2017","unstructured":"Britschgi, A. et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ER\u03b1. Nature 541, 541\u2013545 (2017).","journal-title":"Nature"},{"key":"1766_CR48","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.tim.2023.07.006","volume":"31","author":"L Sarkar","year":"2023","unstructured":"Sarkar, L., Liu, G. & Gack, M. U. ISG15: its roles in SARS-CoV-2 and other viral infections. Trends Microbiol 31, 1262\u20131275 (2023).","journal-title":"Trends Microbiol"},{"key":"1766_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113277","volume":"42","author":"C Lin","year":"2023","unstructured":"Lin, C. et al. Regulation of STING activity in DNA sensing by ISG15 modification. Cell Rep 42, 113277 (2023).","journal-title":"Cell Rep"},{"key":"1766_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","volume":"16","author":"YC Perng","year":"2018","unstructured":"Perng, Y. C. & Lenschow, D. J. ISG15 in antiviral immunity and beyond. Nat Rev Microbiol 16, 423\u2013439 (2018).","journal-title":"Nat Rev Microbiol"},{"key":"1766_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04135-1","volume":"21","author":"T Qu","year":"2023","unstructured":"Qu, T. et al. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma. J Transl Med. 21, 341 (2023).","journal-title":"J Transl Med"},{"key":"1766_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216080","volume":"556","author":"HM Nguyen","year":"2023","unstructured":"Nguyen, H. M. et al. Interferon stimulated gene 15 (ISG15) in cancer: an update. Cancer Lett 556, 216080 (2023).","journal-title":"Cancer Lett"},{"key":"1766_CR53","doi-asserted-by":"publisher","first-page":"e2104162118","DOI":"10.1073\/pnas.2104162118","volume":"118","author":"W Wu","year":"2021","unstructured":"Wu, W. et al. Drivers and suppressors of triple-negative breast cancer. Proc Natl Acad Sci USA 118, e2104162118 (2021).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1766_CR54","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.3390\/ijms20174274","volume":"20","author":"YB Jarrar","year":"2019","unstructured":"Jarrar, Y. B. & Lee, S. J. Molecular functionality of cytochrome P450 4 (CYP4) genetic polymorphisms and their clinical implications. Int J Mol Sci 20, 4274 (2019).","journal-title":"Int J Mol Sci"},{"key":"1766_CR55","doi-asserted-by":"publisher","first-page":"e2105222","DOI":"10.1002\/advs.202105222","volume":"9","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Fusobacterium nucleatum promotes colorectal cancer cell to acquire stem cell-like features by manipulating lipid droplet-mediated numb degradation. Adv Sci (Weinh) 9, e2105222 (2022).","journal-title":"Adv Sci (Weinh)"},{"key":"1766_CR56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/jcm9010087","volume":"9","author":"BJ Hershey","year":"2019","unstructured":"Hershey, B. J., Vazzana, R., Joppi, D. L. & Havas, K. M. Lipid droplets define a sub-population of breast cancer stem cells. J Clin Med 9, 87 (2019).","journal-title":"J Clin Med"},{"key":"1766_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/genes12010099","volume":"12","author":"K Kuramoto","year":"2021","unstructured":"Kuramoto, K. et al. Inhibition of the lipid droplet-peroxisome proliferator-activated receptor \u03b1 axis suppresses cancer stem cell properties. Genes 12, 99 (2021).","journal-title":"Genes"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01766-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:21:06Z","timestamp":1785810066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01766-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}